Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD

1,044.66

-12.36 (-1.17%)

At close: Jul 2, 2024, 4:00 PM

1,045.10

+0.44 (0.04%)

After-hours: Jul 2, 2024, 7:25 PM EDT

Regeneron Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1995
Net Income	3,954	4,338	8,075	3,513	2,116	Upgrade
Depreciation & Amortization	421	341.4	286.2	235.9	210.3	Upgrade
Share-Based Compensation	885	725	601.7	432	464.3	Upgrade
Other Operating Activities	-665.6	-389.9	-1,881.9	-1,563	-360.4	Upgrade
Operating Cash Flow	4,594	5,015	7,081	2,618	2,430	Upgrade
Operating Cash Flow Growth	-8.39%	-29.18%	170.47%	7.74%	10.70%	Upgrade
Capital Expenditures	-718.6	-590.1	-551.9	-614.6	-429.6	Upgrade
Acquisitions	-262.7	-1,257.1	0	0	0	Upgrade
Change in Investments	-2,203.8	-1,937.4	-4,832.8	544	-1,598.2	Upgrade
Investing Cash Flow	-3,185.1	-3,784.6	-5,384.7	-70.6	-2,027.8	Upgrade
Share Issuance / Repurchase	-1,790.1	-1,009	-1,005.8	-3,952.4	-252.1	Upgrade
Debt Issued / Paid	0	0	0	1,982	0	Upgrade
Financing Cash Flow	-1,790.1	-1,009	-1,005.8	-1,970.5	-252.1	Upgrade
Exchange Rate Effect	-0.4	0	0	0	0	Upgrade
Net Cash Flow	-381.6	221.3	690.8	577	150.1	Upgrade
Free Cash Flow	3,875	4,425	6,529	2,004	2,000	Upgrade
Free Cash Flow Growth	-12.42%	-32.23%	225.90%	0.15%	10.40%	Upgrade
Free Cash Flow Margin	29.54%	36.35%	40.63%	23.58%	30.51%	Upgrade
Free Cash Flow Per Share	36.32	41.31	61.77	18.62	18.32	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).